No contamination found in samples of eye drops linked to US deaths: Report

Indian tests found the samples to be of standard quality, the report said, nearly two months after U.S. agencies warned against using the Artificial Tears eye drops

Global Pharma Healthcare
Photo: Website
Reuters NEW DELHI
2 min read Last Updated : Apr 04 2023 | 10:53 PM IST
No contamination was found in samples of eye drops made by India's Global Pharma Healthcare, a product linked to three deaths and blindness in some patients in the U.S., broadcaster NDTV reported on Tuesday citing India's health ministry sources.
 
Indian tests found the samples to be of "standard quality", the report said, nearly two months after U.S. agencies warned against using the Artificial Tears eye drops, citing potential contamination by drug-resistant bacteria.
 
Spokespeople for India's health ministry and Global Pharma Healthcare Pvt Ltd did not immediately respond to a request for comment.
 
The company issued a nationwide voluntary recall of the product in February due to possible contamination, according to the U.S. Food and Drug Administration (FDA), which said the firm had violated good manufacturing practices.
 
The U.S. Centers for Disease Control and Prevention (CDC) had identified the presence of "a rare strain of extensively drug-resistant" bacteria in 68 patients in 16 states, most of whom reported using Artificial Tears eye drops, as of March 14.
 
At least three people have died, and there have been eight reports of vision loss and four reports of surgical removal of an eyeball, according to the CDC.
 
The incident follows the deaths of at least 70 children in Gambia and 19 children in Uzbekistan last year that were linked to Indian-made cough syrups, which hurt the country's image as the "pharmacy of the world".

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :United States

First Published: Apr 04 2023 | 7:59 PM IST

Next Story